Transcranial Magnetic Stimulation (TMS)

What It Is

Transcranial magnetic stimulation is a clinical, non-invasive neuromodulation procedure in which a coil placed near the scalp generates brief, focused magnetic pulses that induce small electrical currents in the underlying cortex. Those currents can either excite or inhibit neuronal firing depending on the stimulation frequency and protocol used. Repetitive TMS — where pulses are delivered in rapid trains rather than single shots — has become the primary form used in psychiatric treatment. This is not a consumer product. TMS requires a physician referral, a psychiatric evaluation, a trained technician to administer each session, and a medical device cleared by the FDA. Sessions typically occur five days per week for four to six weeks, each lasting twenty to forty minutes. Mentioning this upfront matters because TMS is sometimes described in wellness contexts as though it were interchangeable with wearable devices, and it is not. The friction is intentional and carries clinical meaning.

The Science

The core target in depression treatment is the left dorsolateral prefrontal cortex (DLPFC), a region consistently underactive in major depressive disorder. High-frequency rTMS at 10 Hz or above applied to the left DLPFC is excitatory — it tends to increase local neuronal activity and, over a course of treatment, appears to normalize connectivity in the prefrontal-limbic circuits implicated in mood regulation. The mechanism resembles long-term potentiation: repeated stimulation across sessions produces synaptic changes that outlast any individual pulse. A newer protocol called theta-burst stimulation (TBS) delivers a week's worth of traditional rTMS in approximately three minutes, reducing per-session time while producing comparable outcomes.

The pivotal evidence that supported FDA clearance came from a multisite randomized controlled trial by O'Reardon et al. (2007) in Biological Psychiatry, which found active TMS significantly superior to sham in patients with treatment-resistant major depressive disorder who had failed at least one antidepressant trial. The response rate was modest by pharmaceutical standards — roughly 24% versus 12% for sham — but the population was defined by prior treatment failure, which is a genuinely difficult clinical problem. Subsequent naturalistic studies in less treatment-resistant populations have shown higher response rates, often 50–60%.

For OCD, the FDA cleared deep TMS using a specialized H7 coil targeting the dorsomedial prefrontal cortex and anterior cingulate in 2018. The pivotal trial, by Carmi et al. (2019) in the American Journal of Psychiatry, found that 38% of patients receiving active dTMS achieved a response (defined as greater than 30% reduction on the Yale-Brown Obsessive Compulsive Scale), compared to 11% with sham stimulation. The protocol involved symptom provocation immediately before stimulation, which appears to enhance efficacy by activating the target circuit.

Off-label applications are expanding. Evidence exists for TMS in PTSD, chronic pain, tinnitus, smoking cessation, and certain anxiety disorders, but none of these carry FDA clearance, and the evidence varies considerably in quality. The field has also moved toward personalized targeting, using individual neuroimaging data to identify the precise stimulation site most likely to benefit a given patient. This is still largely a research development, not standard clinical practice.

Who Should Use It

TMS is most clearly indicated for adults with major depressive disorder who have had an inadequate response to at least one antidepressant medication — this is the primary FDA-cleared indication. It is also indicated for OCD in adults. The treatment is worth considering when antidepressants have failed, caused intolerable side effects, or when a patient needs to avoid systemic medications for other reasons (pregnancy, drug interactions, or occupational restrictions). Because TMS has no systemic side effects and does not affect cognition in the way that ECT can, it occupies a distinct clinical niche for patients who are resistant to medication but not severe enough to require inpatient intervention. Referrals typically come through psychiatrists.

Who Should Not Use It

Absolute contraindications include any metal implanted in or near the head: cochlear implants, deep brain stimulators, aneurysm clips, magnetic dental implants, or metallic fragments near the orbit or skull. TMS should not be used in individuals with a history of seizures or a diagnosed seizure disorder — the magnetic pulse can lower seizure threshold. Relative contraindications include pregnancy (particularly in the first trimester, where data are limited), severe claustrophobia that makes the procedure intolerable, and active psychosis where the treatment environment and cooperation required may not be manageable. TMS is not a substitute for crisis intervention in acute suicidality.

How to Get Started

Get a psychiatric evaluation: TMS requires a referral, typically from a psychiatrist or a primary care physician working with a psychiatrist. The evaluation assesses diagnosis, prior treatment history, and contraindications.
Check insurance and clinic options: Most major U.S. insurers now cover TMS for depression after one or two failed antidepressants. Coverage for OCD is newer and less consistent. Costs without insurance can exceed $10,000 for a full course.
Understand the time commitment: A standard course is 30–36 sessions over six weeks, five days per week. Accelerated protocols (multiple sessions per day) are emerging but not yet standard of care everywhere.
Expect motor threshold calibration: The first session involves identifying your motor threshold — the stimulation intensity that produces a visible thumb twitch — to calibrate dosing. This takes 15–20 minutes.
Plan for a maintenance strategy: Roughly 50–70% of responders maintain benefit for six months or more after acute treatment. Some patients benefit from periodic maintenance sessions.

Common Questions

How is TMS different from ECT?
Electroconvulsive therapy passes electrical current directly through the brain to induce a seizure and requires general anesthesia. TMS uses magnetic fields to induce much smaller, sub-seizure currents at targeted sites, requires no anesthesia, and does not produce significant cognitive side effects. ECT remains more effective for the most severe, treatment-resistant cases, but TMS offers a substantially better tolerability and safety profile for a wide range of patients.

What does it feel like?
Most patients describe a tapping or clicking sensation on the scalp and a brief involuntary twitch of the jaw or face muscles when the coil is near the motor strip. Many find the first few sessions mildly uncomfortable; most adjust within a week. Headache is the most commonly reported side effect and is typically mild and transient.

How quickly do effects appear?
Antidepressant response typically emerges after two to four weeks of daily treatment. Unlike antidepressants, there is often less lag in subjective experience once a response begins — patients frequently describe a gradual brightening of mood rather than a delayed biochemical shift. Non-response by the end of week four is generally a signal to reassess the protocol or target.

Can TMS be combined with medication?
Yes, and it frequently is. Most clinical trials have been conducted in patients continuing their existing medications. There is no strong evidence that antidepressants reduce TMS efficacy, and some evidence suggests certain combinations may be additive.